Because CRP elevation as an immune regulator alone was not controlling ALS disease progression, we evaluated plasma TGFB1 to test whether there would be evidence for alpha 2 macroglobulin (A2M) activation, another major component of the humoral innate immune system [24], in patients responsive clinically to NP001. Here, A2M is linked to amyotrophic lateral sclerosis.